冰冻切片分析辅助MRI靶向前列腺穿刺:FAST随机试验结果
FAST试验将160例PI-RADS≥4男性随机分为标准联合穿刺组与冰冻切片分析(FSA)引导的以MRI靶向穿刺为主组。FSA组在靶向穿刺阳性时省略系统穿刺,临床显著前列腺癌(csPCa)检出率非劣于标准联合穿刺(93%对97%),且中位穿刺针数由15针降至3针。
要点
- FSA引导策略在csPCa检出上非劣于标准联合穿刺,风险差5.0%(95%CI -5.2-14.7)。
- FSA组中位穿刺针数由15针显著降至3针(p<0.001)。
- FSA组疼痛、不适、肉眼血尿及血精均显著低于标准组(均p<0.05)。
核心结论
- 在mpMRI可疑病灶男性中,FSA引导的靶向穿刺即时评估策略对csPCa检出非劣于标准联合穿刺,并大幅减少穿刺针数与患者负担。
研究设计与样本
- 前瞻性随机试验纳入PI-RADS≥4病灶男性160例,随机分为标准联合穿刺组(A组80例)与FSA引导的以MRI靶向穿刺为主组(B组80例)。
- B组先取3条靶向穿刺针,其中2条立即行FSA;仅当FSA阴性或不确定时才追加系统穿刺。
- 主要终点为csPCa(ISUP分级组≥2)检出,预设非劣效界值为-10个百分点。
主要发现
- csPCa检出率A组93%、B组97%,风险差5.0%(95%CI -5.2-14.7),满足非劣效标准。
- B组中位穿刺针数由15针降至3针(p<0.001)。
- B组疼痛、不适、肉眼血尿及血精均显著低于A组(均p<0.05)。
关键数值与推荐
- 非劣效界值预设为-10个百分点,实际风险差5.0%(95%CI -5.2-14.7)。
- B组靶向穿刺3条,其中2条行FSA;FSA阴性或不确定时追加系统穿刺。
临床怎么用
- 对PI-RADS≥4病灶,可优先行MRI靶向穿刺并联合FSA即时评估,FSA阳性时省略系统穿刺以减少针数与并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) targeted prostate biopsy is still commonly combined with systematic biopsy, resulting in a high number of extracted biopsy cores. This study evaluated whether a frozen section analysis (FSA) guided biopsy strategy enabling immediate assessment of targeted biopsy and omitting systematic biopsy in case of clinically significant prostate cancer (csPCa) is non-inferior to standard combined biopsy while substantially reducing the number of biopsy cores. MATERIAL AND METHODS: In this prospective randomized trial, men with PI-RADS ≥ 4 lesions were randomized to standard combined biopsy (Arm A) or FSA guided primarily MRI-targeted biopsy (Arm B). In Arm B, three targeted cores were obtained, with two immediately analyzed by FSA. Additional systematic biopsy was performed only if FSA was negative or inconclusive. The primary endpoint was detection of csPCa (ISUP grade group ≥2). A non-inferiority margin of -10 %age points was prespecified. RESULTS: A total of 160 patients were randomized (Arm A: 80, Arm B: 80). csPCa detection rates were 93% in Arm A and 97% in Arm B, yielding a risk difference of 5.0% (95% CI -5.2-14.7), meeting non-inferiority criteria. The median number of biopsy cores was reduced from 15 to 3 in Arm B (p < 0.001). Pain, discomfort, macrohematuria, and hematospermia were significantly lower in the experimental arm (all p < 0.05). CONCLUSIONS: FSA guided prostate biopsy enabling immediate assessment of targeted biopsy cores is safe, minimally invasive, and non-inferior regarding the detection of csPCa to standard biopsy in men with suspicious mpMRI lesions. This approach substantially reduces biopsy cores and patient burden by omitting systematic biopsy in case of positive FSA while maintaining oncological safety.
引用
- Jahnen M, Schwamborn K, Sauter A, et al. Frozen section analysis assisted MRI targeted prostate biopsy - results of the randomized clinical FAST trial. Eur J Cancer. 2026. PMID: 42858622. doi:10.1016/j.ejca.2026.117772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。